Le Lézard
Classified in: Health, Science and technology, Business
Subjects: FNC, PDT

Chronolife Announces Commercial Availability of Biometric Nexkintm T-Shirt; Closes New Round of Funding


SAN DIEGO, Dec. 12, 2019 /PRNewswire/ -- Chronolife, an artificial intelligence company specializing in digital health, today announced the commercial launch of Nexkintm, a groundbreaking washable smart T-shirt that monitors six key physiological parameters to enable prevention, risk reduction, and remote monitoring. The announcement follows Nexkintm receiving the CE (Conformité Européenne) mark, certifying it as meeting all safety and performance requirements for sale in the European Union, and came as Chronolife announced the closing of new fundraising to support its commercial and industrial phase.

The Nexkintm platform uses cutting-edge wearable electronics to integrate 10 biometric scanners into a comfortable, machine-washable T-shirt capable of continuously recording a user's electrocardiogram, abdominal and thoracic breathing, body temperature, physical activity, and pulmonary impedance. Data from the shirt is transmitted via Bluetooth to the user's smartphone, where data from multiple sensors can be integrated using Chronolife's unique HOTS (Hierarchy Of event-based Time Surfaces) algorithms to deliver accurate and actionable health insights, which can subsequently be downloaded or transferred to secure servers for review by health professionals.

Comfortable enough for round-the-clock use, and combining a 24-hour battery life with the ability to fully recharge in just a few hours, Chronolife's Nexkintm technology's combination of AI-powered real-time analytics and next-generation wearable sensors has the potential to revolutionize fields including aging-in-place, senior care, occupational health and safety, sports rehabilitation, military training, and performance management.

"The Nexkintm T-shirt makes accurate, unobtrusive continuous health monitoring both affordable and convenient across a wide range of industries and functionalities, from pharmaceutical testing to senior care," said Laurent Vandebrouck, CEO of Chronolife. "By combining wearable electronics with advanced AI-powered analytics, we're delivering biometric monitoring capabilities that will revolutionize the way researchers and healthcare professionals will eventually interact with patients."   

The commercial launch of Nexkintm will allow Chronolife's clients and partners to explore ways to deploy and test the technology in clinical and other settings, including:

Having received the CE mark, Nexkintm is certified as meeting all safety and performance requirements to operate in the European Union. Chronolife also received Federal Communications Commission (FCC) approval this summer, certifying that the Nexkintm shirt's Bluetooth connectivity meets all U.S. regulatory requirements. Nexkintm should receive medical certification in Europe beginning 2020 and Food and Drug Administration (FDA) approval in the U.S. by the end of 2020.

Chronolife today also announced that it has secured funding to support its industrial and commercial plan execution from three investors:

"AI and wearable technologies are dramatically changing the healthcare and research sectors, and Chronolife is at the very forefront of that movement," said Bernard Gilly, executive chairman of iBionext. "This commercial launch is just the beginning: the potential applications for the Nexkintm T-shirt are almost endless."

About Chronolife
Co-founded with iBionext, Chronolife is an artificial intelligence company specializing in digital health. Its patented technology is a unique neuromorphic algorithm called HOTS (Hierarchy Of event-based Time Surfaces), which analyzes several data flows continuously, to characterize clinical events. Chronolife has developed a smart wearable called Nexkintm that integrates various sensors to monitor physiological data continuously. This data is analyzed by the smartphone application on a patient's phone that uses HOTS technology to conduct data fusion. It is capable of detecting changes in a patient's health and triggering alerts to healthcare professionals to predict acute pathological episodes.

Media Contact:
David Wamsley
415-259-9104
dave@rosebudpr.io

SOURCE Chronolife


These press releases may also interest you

at 17:25
Horizon Therapeutics plc today announced that The New England Journal of Medicine has published comprehensive results of the Phase 3 OPTIC clinical trial evaluating TEPEZZAtm (teprotumumab-trbw) for Thyroid Eye Disease (TED). OPTIC is part of the...

at 17:10
HEXO Corp. ("HEXO" or the "Company") today announced it has closed its previously announced registered direct offering with institutional investors (the "Offering"). Under the Offering, the Company sold 11,976,048 common shares at an offering price...

at 17:05
Auxly Cannabis Group Inc. ("Auxly" or the "Company") is pleased to announce that it has been included in the newly created S&P/TSX Cannabis Index ("XCAN"), which measures the performance of a select group of issuers trading on the TSX and TSX...

at 17:00
ACDIS, the Association of Clinical Documentation Integrity Specialists, is excited to announce the final agenda of the 2020 annual conference. This year's conference takes place May 5-8 at the Mirage Hotel & Casino in Las Vegas, with the option to...

at 17:00
The San Francisco employment law attorneys at Blumenthal Nordrehaug Bhowmik De Blouw LLP, filed a class action lawsuit against The Permanente Medical Group, Inc., alleging that the company did not provide their employees with meal and rest breaks and...

at 17:00
The ENDOPRO Elite is the world's first cordless hand held camera system designed for multispecialty point of care/office use. Clinicians can now enhance their practices and provide their patients with state of the art visualization technology with...



News published on 12 december 2019 at 19:24 and distributed by: